Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.0452W HIGH $2.01
Volume
10.16 M
Value Traded
8.38 M
Short % Float
13.05%
+1.67%Week
-12.86%1 Month
-18.67%3 Month
-26.95%6 Month
-11.72%5 Year
-83.07%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
783.82 M
EPS (TTM)
-0.11
P/E Ratio
-
Ent. Value
578.98 M
Total Shares
642.14 M
Float Shares
633.28 M
Insiders
1.43%
Institutions
73.23%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
GERN Catalyst Timeline
Dated clinical, regulatory and corporate events for Geron Corporation
Catalyst Timeline
Dated clinical, regulatory & corporate events for Geron Corporation
608Total events
6Upcoming
110Tier-1 (high impact)
2009 to 2028Coverage
Upcoming catalysts 2
Event history 50
●Full ResultsImetelstatApprovedClinical Data
Updated overall survival analysis of imetelstat in relapsed/refractory myelofibrosis from IMbark versus real-world data
Relapsed or Refractory Myelofibrosissource ↗
◆Full ResultsImetelstatApprovedClinical Data
Updated OS analysis of imetelstat in relapsed/refractory myelofibrosis from IMbark vs real-world data presented at SOHO 2026
relapsed or refractory myelofibrosissource ↗
●Oral PresentationImetelstatApprovedPresentation
Updated OS analysis of imetelstat in relapsed/refractory myelofibrosis from IMbark vs real-world data presented at SOHO 2026
relapsed or refractory myelofibrosissource ↗
◆Full ResultsImetelstatApprovedClinical Data
Updated OS analysis of imetelstat in relapsed/refractory myelofibrosis from IMbark versus real-world data
relapsed or refractory myelofibrosissource ↗
●Quarterly UpdateRYTELOApprovedCorporate
Q2 2026 financial results reported
lower-risk myelodysplastic syndromessource ↗
▲Quarterly UpdateRYTELOApprovedCorporate
RYTELO demand grew 5% in Q2 2026
lower-risk myelodysplastic syndromessource ↗
◆Oral PresentationPresentation
Geron management to participate in fireside chat at Goldman Sachs 47th Annual Global Healthcare Conference
▲Oral PresentationRYTELOApprovedPresentation
Real-world evidence study presented at EHA 2026
lower-risk myelodysplastic syndromessource ↗
▲Oral PresentationImetelstatApprovedPresentation
Updated OS analysis from IMbark presented at ASCO 2026
relapsed/refractory myelofibrosissource ↗
◆Oral PresentationPresentation
Bank of America Securities 2026 Healthcare Conference presentation
▲Quarterly UpdateCorporate
Existing cash plus anticipated RYTELO revenues expected to fund operations for foreseeable future
▲PublicationImetelstatApprovedPresentation
Publication in Blood Cancer Journal on treatment-emergent cytopenias and clinical responses
lower-risk myelodysplastic syndromes (LR-MDS)source ↗
▲Manufacturing MilestoneRYTELOApprovedCMC / Inspection
Validation of a second supplier for RYTELO supply chain
●Management ChangeCorporate
Appointment of Timothy Williams as EVP, Chief Legal Officer and Corporate Secretary
●Management ChangeCorporate
Appointment of Timothy Williams as EVP, Chief Legal Officer and Corporate Secretary
◆Oral PresentationPresentation
Fireside chat at 25th Annual Needham Virtual Healthcare Conference
◆Interim AnalysisImetelstatApprovedTrial
Expected interim analysis for overall survival in IMpactMF
relapsed/refractory myelofibrosissource ↗
▲Quarterly UpdateRYTELOApprovedCorporate
RYTELO net product revenue of $51.8 million in Q1 2026
lower-risk myelodysplastic syndromes (LR-MDS)source ↗
●Quarterly UpdateCorporate
Cash, cash equivalents, restricted cash and marketable securities of $341M as of March 31, 2026
◆Interim AnalysisImetelstatApprovedTrial
Interim analysis expected in early 2026
JAKi relapsed/refractory myelofibrosis (R/R MF)source ↗
◆Full ResultsImetelstatApprovedClinical Data
Final analysis for IMpactMF in R/R MF
relapsed/refractory myelofibrosis (R/R MF)source ↗
◆Trial CompletionImetelstatApprovedTrial
Final analysis expected for IMpactMF
myelofibrosis (MF) relapsed/refractory to JAK-inhibitorssource ↗
▲Oral PresentationRYTELOApprovedPresentation
Oral presentation at ASH 2025: Correlation between Treatment-Emergent Cytopenias and Clinical Response with Imetelstat in LR-MDS
lower-risk myelodysplastic syndromessource ↗
▲Poster PresentationRYTELOApprovedPresentation
Poster at ASH 2025: Long-Term Outcomes and Overall Survival from IMerge
lower-risk myelodysplastic syndromessource ↗
▼Restructuring LayoffsCorporate
Workforce reduction of approximately one-third implemented in December 2025
◆Oral PresentationImetelstatApprovedPresentation
Oral presentation at ASH 2025 on IMerge trial data
lower-risk MDSsource ↗
●Poster PresentationImetelstatApprovedPresentation
Poster presentation at ASH 2025 on IMbark trial data
relapsed refractory myelofibrosissource ↗
◆Management ChangeCorporate
Bryan Ridgell appointed SVP, Portfolio and Project Management and Chief of Staff
▲Enrollment CompleteImetelstatApprovedTrial
Completed enrollment of 320 patients in IMpactMF trial
relapsed refractory myelofibrosissource ↗
▲Enrollment MilestoneImetelstatApprovedTrial
IMpactMF enrollment over 95% as of end of July 2025
relapsed/refractory myelofibrosissource ↗
▲EU ApprovalRYTELOApprovedEx-US Regulatory
EC granted marketing authorization for RYTELO in LR-MDS
lower-risk myelodysplastic syndromes (LR-MDS)source ↗
▲Enrollment UpdateImetelstatApprovedTrial
Approximately 85% enrollment reached in IMpactMF trial
relapsed refractory myelofibrosis (R/R MF)source ↗
Past FDA Catalysts and PDUFA Decisions
How GERN actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2024-06-07 | Imetelstat (GRN163L) | PDUFA Date Approved | PDUFA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D37 / 100
Pipeline Score
$32M
Pipeline Value
$475M
Commercial Value
Overvalued
Valuation Signal
1
Drugs Scored
0.1x
rNPV / MCap
Top 48%
Micro Cap(rank 316 of 658)
Percentile Rank
Geron Corporation faces pipeline headwinds (37/100), with $81M risk-adjusted pipeline value, led by Imetelstat in Recurrent Childhood Acute Myeloid Leukemia (Phase 1).
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026; product lines: last four quarters to Jun 2026 (10-K and 10-Q)) Revenue $204.6M x 2.3 = $475M
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| RYTELO | $204M | $164M | +24.5% |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Imetelstat Small moleculeNCT05371964 | Myelofibrosis | Phase 3 | ACTIVE NOT_RECRUITING | 464 | Aug 1, 2028 |
Clinical Trial Results
Readouts, endpoints and source filings for every GERN program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Spiegel Robert J.Director | Grant/Award | 6,103 205,810 held | $1.28 | 06/30/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in GERN
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 0.5 % (-50 %) | 54.80 M | 42.81 M | -32.87% ( -20.96 M) |
GERN Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How GERN ranks across every disease it competes in
Competitive Position is a premium feature
See how GERN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialGERN News
GERN▼ -5.3%on this news
September 22, 2026
The study published in the Journal of Clinical Medicine highlights the synergistic effects of combining the telomerase inhibitor Imetelstat with the BCL-2 inhibitor Venetoclax in treating Acute Myeloid Leukemia (AML). The results from both cellular and animal models indicate that this combination enhances apoptosis and improves survival rates, suggesting a promising therapeutic strategy for AML patients.
Read more →GERNGeron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Geron Corporation has granted stock options to nine new employees as part of their employment inducement strategy. The options, totaling 821,250 shares, have a ten-year term and will vest over four years. This move aligns with Nasdaq Listing Rule 5635(c)(4) and is part of Geron's ongoing efforts to enhance its workforce in the hematology sector.
Read more →GERN▼ -7.3%on this news
September 9, 2026
The article discusses an updated analysis of overall survival rates for Imetelstat in patients with relapsed or refractory myelofibrosis, comparing results from the IMbark study to real-world data. The post hoc analysis indicates improved survival outcomes and offers insights into treatment patterns following extended follow-up. This research contributes to understanding the efficacy of Imetelstat in clinical settings.
Read more →GERN▲ +7.4%on this news
Geron to Present at Upcoming Investor Conferences
Geron Corporation announced participation in two upcoming investor conferences in September 2026. The management team will engage in fireside chats at the Cantor Global Healthcare Conference and the H.C. Wainwright 28th Annual Global Investment Conference. The company continues to focus on hematology and the development of its drug RYTELO® for blood cancer patients.
Read more →GERN▲ +21.6%on this news
Geron Corporation Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Geron Corporation reported a strong financial performance for Q2 2026, with RYTELO net product revenue reaching $57.5 million, an 11% increase from Q1 2026. The company anticipates continued growth in demand for RYTELO, especially among lower-risk myelodysplastic syndromes patients. Despite a slight increase in net loss, Geron remains optimistic about its financial outlook and strategic initiatives.
Read more →GERNGeron Plans to Announce Second Quarter 2026 Financial Results on August 5, 2026
Geron Corporation will announce its second quarter 2026 financial results on August 5, 2026. The announcement will be made via press release before the market opens, followed by a conference call and webcast at 8:00 a.m. ET. Geron is known for its first-in-class telomerase inhibitor, RYTELO®, approved for treating certain blood cancer patients.
Read more →GERNGeron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Geron Corporation has granted a stock option to Chinmaya Rath, its new Chief Business Officer, as part of his employment inducement. The option allows for the purchase of 1,700,000 shares at an exercise price of $1.42 per share and vests over four years. This grant was approved by the Compensation Committee in accordance with Nasdaq regulations.
Read more →GERN▼ -5.3%on this news
Geron Announces Appointment of Chinmaya Rath as Chief Business Officer
Geron Corporation has appointed Chinmaya Rath as Chief Business Officer, aiming to enhance strategic execution and maximize the value of RYTELO. Rath brings over 25 years of experience in biopharma, having previously held significant roles at Novartis and other companies. Geron is focused on expanding its presence in hematology and advancing its clinical trials.
Read more →GERNGeron to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
Geron Corporation will participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026. The management team will engage in a fireside chat at 8:40 a.m. ET in Miami, FL. Geron is known for its first-in-class telomerase inhibitor, RYTELO® (imetelstat), which is approved for treating specific blood cancer patients.
Read more →GERNGeron Corporation Reports First Quarter 2026 Financial Results and Recent Business Highlights
Geron Corporation reported a strong financial performance for Q1 2026, with RYTELO net product revenue reaching $51.8 million, an 8% increase from the previous quarter. The company also announced a strengthened leadership team and maintained a solid cash position of $341 million. Despite a net loss of $3.6 million, Geron remains optimistic about future growth and plans for RYTELO in the U.S. and Europe.
Read more →GERN▲ +5.1%on this newsshared move
Geron Plans to Present at Upcoming Investor Conferences
Geron Corporation has announced upcoming presentations at major investor conferences, including the Bank of America Securities 2026 Healthcare Conference and the 2026 Stifel Virtual Targeted Oncology Forum. These presentations are scheduled for May 12 and May 20, 2026, respectively. Geron aims to showcase its initiatives in changing the course of blood cancer, positioning itself for potential investor interest.
Read more →GERNGeron Plans to Announce First Quarter 2026 Financial Results on May 6, 2026
Geron Corporation plans to release its first quarter 2026 financial results on May 6, 2026. The announcement will be made before the market opens, followed by a conference call at 8:00 a.m. ET. Geron is focused on blood cancer treatments, particularly with its telomerase inhibitor RYTELO® and ongoing clinical trials.
Read more →GERNGeron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 20, 2026
Geron Corporation announced the grant of stock options to nine new employees as an inducement for their acceptance of employment. The options, totaling 855,000 shares, have an exercise price of $1.68 per share and will vest over four years. This move aligns with Nasdaq Listing Rule 5635(c)(4) and aims to bolster the company's workforce as it continues its focus on blood cancer therapies.
Read more →GERNGeron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - April 14, 2026
Geron Corporation announced the granting of a stock option to Timothy Williams, its new Executive Vice President, as part of his employment agreement. The option allows him to purchase 2,500,000 shares at an exercise price of $1.73, vesting over four years. This grant was approved by the Compensation Committee under Nasdaq rules.
Read more →GERNGeron Announces Appointment of Timothy Williams as Executive Vice President, Chief Legal Officer and Corporate Secretary
Geron Corporation has appointed Timothy Williams as Executive Vice President, Chief Legal Officer, and Corporate Secretary. Williams, who has a strong background in the biopharmaceutical industry, is expected to provide strategic counsel as Geron advances its mission in hematology. His previous experience includes roles at Vanda Pharmaceuticals and AgNovos Bioscience.
Read more →About Geron Corporation
Headquarters919 EAST HILLSDALE BOULEVARD, FOSTER CITY, CA, 94404
BIOPHARMAWATCH ELITE PLUS
Trade the next GERN catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime